| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d37cd87266bab5d87dae64b44f12f16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14c370d027f7d7ff762243b9ba4269e5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-353 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78873dbc1d2e960d171ab3338b9159dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8109de804f34e438f055c7556fd2a998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b01fe1a1c3af0ce14aefbac08807eda7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79a7c7003aebb611357c127704d2814b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fddbaa33d90ab3499a45247d0b0c46b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cdab542184a21bfbaa4f7e72008092b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7efcdbc51ac13cff468241032ed82756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c51c33d558e87f89288ccd7a000f623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd4780768024a4e6556e114e19e9d713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd1b81fb8d08a1f0e8913c53107c6a1a |
| publicationDate |
2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020223888-A1 |
| titleOfInvention |
Application of epigallocatechin gallate combined with tyrosine kinase inhibitor in preparation of cancer treatment drugs |
| abstract |
An application of epigallocatechin gallate (EGCG) or a compound synthesized with same as a lead compound combined with one or more tyrosine kinase inhibitors in the preparation of cancer treatment drugs, wherein the cancer is an EGFR wild-type tumor. The present combined use is capable of significantly inhibiting the growth of the EGFR wild-type tumor and reducing the side effects of anti-cancer drugs. |
| priorityDate |
2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |